Grau-López L, Teniente-Serra A, Tintoré M, Rovira A, Ramió-Torrenta L, Brieva L, Saiz A, Cano A, Carmona O, Hervás J V, Martínez-Cáceres E M, Ramo-Tello C
Hospital Germans Trias i Pujol, Badalona, Spain/Universitat Autònoma de Barcelona, Spain
Hospital Germans Trias i Pujol, Badalona, Spain/Universitat Autònoma de Barcelona, Spain.
Mult Scler. 2015 Apr;21(5):646-50. doi: 10.1177/1352458514546786. Epub 2014 Aug 21.
Our aim was to investigate differences in immune mechanisms in multiple sclerosis (MS) relapse, after high-dose oral methylprednisolone (oMP) or intravenous methylprednisolone (ivMP). We measured serum cytokines (IL-2, IL-4, IL-6, IL-10, IL-17, TNF-α and IFN-γ) in 39 of 49 MS patients with moderate-severe relapse, whom were treated with ivMP or oMP in a placebo-controlled, non-inferiority clinical trial. We assessed these cytokine levels at baseline and at 1 and 4 weeks post-treatment. The cytokine levels between oMP and ivMP were similar at any time. Proinflammatory cytokines (IL-6 and IFN-γ) were significantly decreased in both groups at week 1 (p = 0.05 / p = 0.03) and at week 4 (p = 0.04 / p = 0.05). This study provides further confirmatory evidence that oMP is not inferior to ivMP.
clinicaltrials.gov identifier: NCT00753792.
我们的目的是研究在多发性硬化症（MS）复发时，大剂量口服甲基泼尼松龙（oMP）或静脉注射甲基泼尼松龙（ivMP）后免疫机制的差异。我们在49例中重度复发的MS患者中的39例中测量了血清细胞因子（IL-2、IL-4、IL-6、IL-10、IL-17、TNF-α和IFN-γ），这些患者在一项安慰剂对照的非劣效性临床试验中接受了ivMP或oMP治疗。我们在基线以及治疗后1周和4周评估了这些细胞因子水平。在任何时间点，oMP和ivMP之间的细胞因子水平相似。两组在第1周（p = 0.05 / p = 0.03）和第4周（p = 0.04 / p = 0.05）时促炎细胞因子（IL-6和IFN-γ）均显著降低。本研究提供了进一步的确证证据，表明oMP并不劣于ivMP。
clinicaltrials.gov标识符：NCT00753792。
